Safety and efficacy of bevacizumab with first-line FOLFIRI for metastatic colorectal cancer: Single center experience

被引：0
|
作者：
Longo, F. [1 ]
De Sanctis, R. [1 ]
Quadrini, S. [1 ]
Stumbo, L. [1 ]
Del Signore, E. [1 ]
Gori, B. [1 ]
De Filippis, L. [1 ]
Di Seri, M. [1 ]
机构：
[1] Policlin Umberto 1, Rome, Italy
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：91 / 92
页数：2
相关论文
共 50 条
  • [1] SAFETY AND EFFICACY OF BEVACIZUMAB WITH FIRST-LINE FOLFIRI FOR METASTATIC COLORECTAL CANCER: SINGLE CENTER EXPERIENCE
    De Sanctis, R.
    Longo, F.
    Gori, B.
    Zivi, A.
    Del Signore, E.
    Proietti, E.
    De Filippis, L.
    Stumbo, L.
    Quadrini, S.
    Di Seri, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 145 - 145
  • [2] The clinical efficacy of FOLFIRI and bevacizumab in combination as first-line therapy of metastatic colorectal cancer
    不详
    CLINICAL COLORECTAL CANCER, 2007, 6 (09) : 621 - 624
  • [3] Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study
    Van Cutsem, E.
    Rivera, F.
    Berry, S.
    Kretzschmar, A.
    Michael, M.
    DiBartolomeo, M.
    Mazier, M. -A.
    Canon, J. -L.
    Georgoulias, V.
    Peeters, M.
    Bridgewater, J.
    Cunningham, D.
    ANNALS OF ONCOLOGY, 2009, 20 (11) : 1842 - 1847
  • [4] A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer
    R López
    M Salgado
    M Reboredo
    C Grande
    J C Méndez
    M Jorge
    C Romero
    G Quintero
    J de la Cámara
    S Candamio
    British Journal of Cancer, 2010, 103 : 1536 - 1541
  • [5] A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer
    Lopez, R.
    Salgado, M.
    Reboredo, M.
    Grande, C.
    Mendez, J. C.
    Jorge, M.
    Romero, C.
    Quintero, G.
    de la Camara, J.
    Candamio, S.
    BRITISH JOURNAL OF CANCER, 2010, 103 (10) : 1536 - 1541
  • [6] FOLFIRI® and Bevacizumab in first-line treatment for colorectal cancer patients: Safety, efficacy and genetic polymorphisms
    Bécouarn Y.
    Cany L.
    Pulido M.
    Beyssac R.
    Texereau P.
    Le Morvan V.
    Béchade D.
    Brunet R.
    Aitouferoukh S.
    Lalet C.
    Mathoulin-Pélissier S.
    Fonck M.
    Robert J.
    BMC Research Notes, 7 (1)
  • [7] EFFECTIVENESS AND SAFETY OF FIRST-LINE BEVACIZUMAB PLUS FOLFIRI IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Pinto, Ana Catarina
    Teixeira, Margarida
    Bonito, Nuno
    Jacinto, Paula
    Ribeiro, Joao
    Gervasio, Helena
    ANNALS OF ONCOLOGY, 2011, 22 : v98 - v98
  • [8] Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer
    Akun, E.
    Okutur, K.
    Seber, S.
    Korkmaz, T.
    Aydin, K.
    Bozkurt, M.
    Namal, E.
    Hasbal, B.
    Tecimer, C.
    Demir, G.
    JOURNAL OF BUON, 2012, 17 (04): : 669 - 676
  • [9] Bevacizumab in First-line Therapy of Metastatic Colorectal Cancer: A Retrospective Comparison of FOLFIRI and XELIRI
    Ocvirk, Janja
    Rebersek, Martina
    Boc, Marko
    ANTICANCER RESEARCH, 2011, 31 (05) : 1777 - 1782
  • [10] PRELIMINARY EFFICACY OF BEVACIZUMAB WITH FIRST LINE CHEMOTHERAPY BY FOLFOX OR FOLFIRI FOR METASTATIC COLORECTAL CANCER (MCRC): AN ALGERIAN EXPERIENCE
    Bensalem, A.
    Bouzid, K.
    ANNALS OF ONCOLOGY, 2009, 20 : 40 - 40
12345